08.24.16
BioTechnique has launched the second phase of manufacturing in partnership with a major, international not-for-profit organization. Under this partnership, BioTechnique will manufacture a commercially-available vaccine product in a new, shelf-stable dosage form. In the first phase of manufacturing, BioTechnique produced the same vaccine product in late 2015. The vaccine met all analytical and release testing specifications and entered the clinic in early 2016.
“We are very pleased to support a major non-profit trust in bringing their novel dosage form to market,” said John Clapham, chief executive officer, BioTechnique. “With the continuation of this live attenuated virus manufacturing partnership, we have broadened our ability meet demand from our customers who need a reliable contract manufacturing partner.”
Located in Madison, WI, BioTechnique’s successful completion of its first project marked its official transition into an operational contract manufacturing organization (CMO) with expertise in cytotoxic and highly potent sterile injectable manufacturing.
“We are very pleased to support a major non-profit trust in bringing their novel dosage form to market,” said John Clapham, chief executive officer, BioTechnique. “With the continuation of this live attenuated virus manufacturing partnership, we have broadened our ability meet demand from our customers who need a reliable contract manufacturing partner.”
Located in Madison, WI, BioTechnique’s successful completion of its first project marked its official transition into an operational contract manufacturing organization (CMO) with expertise in cytotoxic and highly potent sterile injectable manufacturing.